AuraVax Therapeutics Enters into Exclusive License Agreement

AuraVax Therapeutics Enters into Exclusive License Agreement with the University of Houston for Intranasal Vaccine and Therapeutics Technology Platform


AuraVax Therapeutics Enters into Exclusive License Agreement with the University of Houston for Intranasal Vaccine and Therapeutics Technology Platform
--Transaction supports development of AuraVax's lead COVID-19 intranasal program, plus other vaccines and therapeutics targeting respiratory diseases--
News provided by
Share this article
Share this article
HOUSTON, Feb. 3, 2021 /PRNewswire/ -- AuraVax Therapeutics Inc. (www.auravax.com), a pioneering biotech company developing novel intranasal vaccines and therapies to help patients defeat debilitating diseases including COVID-19, today announced it has entered into an exclusive license agreement with the University of Houston (UH) with respect to the intellectual property covering a novel intranasal vaccine and STING agonist technologies. This agreement converts the optioned intellectual property between UH and AuraVax announced on October 12, 2020.

Related Keywords

University Of Houston , Texas , United States , Houston , American , Auravax Theraputics , Navin Varadarajan , Matthewj Meyer , Amr Elnashai , Phi Beta Kappa , Auravax Therapeutics Inc , Prnewswire Auravax Therapeutics Inc , Vax Therapeutics , Biomolecular Engineering , Carnegie Designated Tier One , Gulf Coast Region , Asian American Serving , பல்கலைக்கழகம் ஆஃப் ஹூஸ்டன் , டெக்சாஸ் , ஒன்றுபட்டது மாநிலங்களில் , ஹூஸ்டன் , அமெரிக்கன் , நவீன் வரதராஜன் , ஃபை பீட்டா கப்பா , வ்யாக்ஸ் சிகிச்சை , உயிர் மூலக்கூறு பொறியியல் , கார்னகி நியமிக்கப்பட்ட அடுக்கு ஒன்று , வளைகுடா கடற்கரை பகுதி , ஆசிய அமெரிக்கன் சேவை ,

© 2025 Vimarsana